Multiple pre-clinical models of NSCLC and MTC have been used to highlight the possibility of potent RET inhibition by Pralsetinib, which was FDA-approved for the treatment of RET-altered thyroid cancers in December 2020. This evidence concerns the gene RET and thyroid cancer.